XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $52.74M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.06M
Average 0.03M
XBIT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
XBiotech Inc.NASDAQ: XBIT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $172K fell 94.8% year over year, behind the -90.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 6.2% from the prior quarter. Over 3 fiscal years it compounded at -10.6% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -94.8% toward the trailing-twelve-month pace of -90.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.62M USD
- Year-over-year change
- +106.6%
- 4-year CAGR
- -5.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.62M | +106.6% |
| FY2024 | 2024-12-31 | 1.75M | -46.3% |
| FY2023 | 2023-12-31 | 3.26M | -35.6% |
| FY2022 | 2022-12-31 | 5.06M | +13.4% |
| FY2021 | 2021-12-31 | 4.46M | — |
Stock-Based Compensation vs competitors
How XBIT compares with its peers on the latest reported figures
- XBIT's LTM Mar 2026 stock-based compensation of $465K is the smallest of the 9 companies compared; the peer median is $11.57M.
- Its year-over-year change of -90.1% is the lowest of 8, against a peer median of -31.8%.
- Over three fiscal years its annual growth of -10.6% compares with a peer median of -0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $13.93M | -47.2% | -30.3% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $12.39M | -37.2% | -5.9% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Jun 2024 | $7.27M | — | -29.1% | 891.4% | |
| LTM Apr 2026 | $3.23M | +3574.0% | -47.8% | 179.0% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $465K | -90.1% | -10.6% | — | |
| Peer median (excluding XBIT) | $11.57M | -31.8% | -0.1% | 148.4% | |
Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.41M) | (32.9M) | (24.56M) | (38.53M) | (45.54M) |
| Depreciation & Amortization | 2.65M | 2.61M | 1.74M | 1.75M | 1.69M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 5K |
| Stock-Based Compensation | 4.46M | 5.06M | 3.26M | 1.75M | 3.62M |
| Change in Working Capital | 79.75M | 7.6M | 2.72M | (1.46M) | 3.64M |
| Accounts Receivables | 1.73M | 7.34M | 829K | 77K | 574K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (514K) | 357K | 91K | (364K) | (688K) |
| Other Working Capital | 78.53M | (97K) | 1.8M | (1.17M) | 3.75M |
| Other Non-Cash Items | 4.46M | 2.8M | (1.89M) | 5.53M | (3.33M) |
| Operating Cash Flow | 69.45M | (14.82M) | (18.73M) | (30.96M) | (39.92M) |
| Capital Expenditures | (3.53M) | (585K) | (362K) | (1.3M) | (289K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (63.31M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 61.86M | 0 | 0 |
| Investing Cash Flow | (3.53M) | (63.89M) | 61.5M | (1.3M) | (289K) |
| Debt Repayment | 0 | 0 | 0 | 10.25M | (10.25M) |
| Common Stock Issued | 0 | 0 | 5K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (75M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8M | 0 | (14K) | 200K | 0 |
| Financing Cash Flow | (67.01M) | 0 | (9K) | 10.45M | (10.25M) |
| Effect of Forex Changes | 705K | (961K) | (46K) | (5.53M) | 3.33M |
| Net Change in Cash | (383K) | (79.68M) | 42.72M | (27.35M) | (47.13M) |
| Free Cash Flow | 65.92M | (15.41M) | (19.09M) | (32.27M) | (40.21M) |
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.